Weill Cornell Medicine BioVenture Speaker Series
https://weillcornell.zoom.us/j/98507079952
Passcode: 500100
Weill Cornell Medicine BioVenture Speaker Series
https://weillcornell.zoom.us/j/98507079952
Passcode: 500100
Do you have an idea for a medical device but aren’t sure what to do next or how to produce it? Join us in the brand-new BioVenture eLab for an exciting evening to discuss medical device innovation as we begin a new initiative to gather like-minded individuals interested in the field.
All backgrounds are encouraged to attend: i.e., surgeons, clinicians, researchers, business, graduate students, engineers etc.
Dr. Srivastava is an experienced biotechnology executive and investment analyst. Dr. Srivastava was recently the Chief Financial and Strategy Officer for Abide Therapeutics. Prior to this, she was the Chief Financial and Strategy Officer for Intellia Therapeutics from April 2015 to December 2016. She played an integral role in helping start up Intellia’s financial operations and strategic direction, the Series B private funding, and the initial public offering.
Dr. Srivastava has fifteen years of experience as a stock analyst for biotechnology sector on Wall Street. She was the senior analyst and team leader of the biotechnology group at Goldman Sachs. Prior to that role, Dr. Srivastava was the senior biotechnology analyst at Morgan Stanley and ThinkEquity Partners, LLC, and began her career as a research associate at JP Morgan. Dr. Srivastava has also served as an independent strategy advisor to several high growth potential, therapeutic focused, biotechnology companies.
Dr. Srivastava received her PhD in neuroscience from New York University and her B.Sc from St. Xavier’s College in India.
Dr. Srivastava is an experienced biotechnology executive and investment analyst. Dr. Srivastava was recently the Chief Financial and Strategy Officer for Abide Therapeutics. Prior to this, she was the Chief Financial and Strategy Officer for Intellia Therapeutics from April 2015 to December 2016. She played an integral role in helping start up Intellia’s financial operations and strategic direction, the Series B private funding, and the initial public offering.
Dr. Srivastava has fifteen years of experience as a stock analyst for biotechnology sector on Wall Street. She was the senior analyst and team leader of the biotechnology group at Goldman Sachs. Prior to that role, Dr. Srivastava was the senior biotechnology analyst at Morgan Stanley and ThinkEquity Partners, LLC, and began her career as a research associate at JP Morgan. Dr. Srivastava has also served as an independent strategy advisor to several high growth potential, therapeutic focused, biotechnology companies.
Dr. Srivastava received her PhD in neuroscience from New York University and her B.Sc from St. Xavier’s College in India.
Join us Tuesday, November 24 for a roundtable discussing healthcare entrepreneurship with entrepreneurs from JLABS @ NYC! This panel is part of the Weill Cornell Medicine Accelerating BioVenture Innovation (ABI) entrepreneurship training program that builds teams and business plans around patented technologies from Weill Cornell Medicine, Memorial Sloan Kettering Cancer Center and Rockefeller University.
Speakers include:
Erika Milczek, PhD, Chief Executive Officer and Founder, Curie Co
Kwaku Owusu, MS/MBA, Founder & CEO, Drugviu
Maria Luisa Pineda, PhD, Co-founder & CEO, Envisagenics
Moderated by Stephen Pitt, PhD, Head of JLABS @ US North East
Tuesday, November 24, 2020
5:30-7:00PM
ABI is organized and sponsored by Weill Cornell Medicine’s BioVenture eLab and the Office of BioPharma Alliances & Research Collaborations.